within Pharmacolibrary.Drugs.ATC.R;

model R07AB52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.25,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Nikethamide is a respiratory stimulant previously used to treat respiratory depression and as a circulatory stimulant. It acts primarily through respiratory centers in the medulla. Use has largely been discontinued due to limited efficacy and safety concerns. It is not widely approved or used in modern clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult individuals, as there are no published studies with reported PK models for nikethamide, combinations.</p><h4>References</h4><ol><li>S L Vaisman, L M Gartner,Pharmacologic treatment of neonatal hyperbilirubinemia.,Clinics in perinatology,1975<a href='https://pubmed.ncbi.nlm.nih.gov/1102218/'>https://pubmed.ncbi.nlm.nih.gov/1102218/</a></li><li>I Reile, N Eshuis, N K J Hermkens, B J A van Weerdenburg, M C Feiters, F P J T Rutjes, M Tessari,NMR detection in biofluid extracts at sub-Î¼M concentrations via para-H2 induced hyperpolarization.,The Analyst,2016<a href='https://pubmed.ncbi.nlm.nih.gov/27221513/'>https://pubmed.ncbi.nlm.nih.gov/27221513/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R07AB52;
